Seres Therapeutics (MCRB) to Release Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is projected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($2.1850) per share and revenue of $0.1790 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million. On average, analysts expect Seres Therapeutics to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Seres Therapeutics Stock Down 1.0%

MCRB opened at $4.80 on Wednesday. The stock’s fifty day moving average is $6.63 and its two-hundred day moving average is $9.01. The company has a market capitalization of $46.46 million, a P/E ratio of -0.93 and a beta of 0.09. Seres Therapeutics has a 52 week low of $4.59 and a 52 week high of $29.98.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Seres Therapeutics in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings cut Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen raised Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Zacks Research raised Seres Therapeutics to a “hold” rating in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $17.00.

Hedge Funds Weigh In On Seres Therapeutics

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 1,160 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after buying an additional 3,918 shares during the last quarter. State Street Corp raised its holdings in shares of Seres Therapeutics by 14.0% in the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after buying an additional 4,170 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Seres Therapeutics by 4.8% during the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.